• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[兴奋剂和非兴奋剂对成人注意力缺陷多动障碍(ADHD)的疗效与安全性]

[Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].

作者信息

Golubchik Pavel, Sever Jonatan, Weizman Abraham

机构信息

Geha Mental Health Center, Petah Tikva, Israel.

出版信息

Harefuah. 2011 Oct;150(10):788-90, 814.

PMID:22111124
Abstract

Attention deficit hyperactivity disorder (ADHD) often persists into adulthood. Stimulants, including methylphenidate, as well as non-stimulants, have shown efficacy in treating adult ADHD. Comparative, double blind, placebo controlled studies, in adults with ADHD, demonstrate good efficacy and safety profile. Methylphenidate was found to be tolerable and safe in short term treatment when given in its immediate release and long-acting preparations to adults with ADHD. Methylphenidate treatment is recommended in cases when ADHD diagnosis was confirmed. Follow-up is required with special attention to possible cardiovascular, psychiatric and abusive side effects.

摘要

注意力缺陷多动障碍(ADHD)常常持续至成年期。包括哌甲酯在内的兴奋剂以及非兴奋剂已显示出对成人ADHD的治疗效果。针对患有ADHD的成人进行的比较性、双盲、安慰剂对照研究表明其疗效良好且安全性高。对于患有ADHD的成人,速释和长效制剂的哌甲酯在短期治疗中耐受性良好且安全。确诊为ADHD时,建议使用哌甲酯治疗。需要进行随访,特别关注可能出现的心血管、精神和滥用方面的副作用。

相似文献

1
[Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].[兴奋剂和非兴奋剂对成人注意力缺陷多动障碍(ADHD)的疗效与安全性]
Harefuah. 2011 Oct;150(10):788-90, 814.
2
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.OROS 哌甲酯治疗成人注意力缺陷/多动障碍的疗效与安全性:一项随机、安慰剂对照、双盲、平行组、剂量递增研究。
J Clin Psychopharmacol. 2009 Jun;29(3):239-47. doi: 10.1097/JCP.0b013e3181a390ce.
3
Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.持续释放哌甲酯治疗苯丙胺滥用者注意缺陷多动障碍:一项初步研究。
Drug Alcohol Depend. 2010 Apr 1;108(1-2):130-3. doi: 10.1016/j.drugalcdep.2009.11.006. Epub 2009 Dec 16.
4
Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder.长效哌醋甲酯可降低患有注意缺陷多动障碍的年轻成年司机的碰撞率。
J Clin Psychopharmacol. 2012 Apr;32(2):225-30. doi: 10.1097/JCP.0b013e3182496dc5.
5
Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.延释型哌甲酯治疗 24 周可改善成年 ADHD 的情绪症状。
World J Biol Psychiatry. 2010 Aug;11(5):709-18. doi: 10.3109/15622971003624197.
6
Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.成人注意缺陷多动障碍中安慰剂反应的预测因素:口服渗透压控释系统哌甲酯的 2 项随机试验数据。
J Clin Psychiatry. 2012 Aug;73(8):1097-102. doi: 10.4088/JCP.11m07528. Epub 2012 Jun 12.
7
Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.控释型哌甲酯能否改善核心症状及执行功能缺陷?针对成人注意力缺陷多动障碍的开放标签试验结果
Curr Med Res Opin. 2006 Dec;22(12):2557-66. doi: 10.1185/030079906X154132.
8
[Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment].[注意缺陷多动障碍(ADHD)。哌甲酯中期治疗持续控制症状]
Med Monatsschr Pharm. 2006 Nov;29(11):415-6.
9
Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.在三种注意缺陷多动障碍(ADHD)亚型中,对于速释型哌甲酯依从性差的患者,渗透型口服系统哌甲酯疗效更佳。
Psychiatry Clin Neurosci. 2009 Apr;63(2):167-75. doi: 10.1111/j.1440-1819.2009.01937.x.
10
Focalin XR for ADHD.用于治疗注意力缺陷多动障碍的缓释福洛里诺(Focalin XR)
Med Lett Drugs Ther. 2009 Mar 23;51(1308):22-4.